India, Nov. 3 -- Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application filed for Methylprednisolone Acetate Injectable Suspension USP, 40 mg/mL and 80 mg/mL Single-Dose Vials and 200 mg/5 mL (40 mg/mL), 400 mg/10 mL (40 mg/mL), and 400 mg/5 mL (80 mg/mL) Multiple-Dose Vials.The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Depo-Medrol Injectable Suspension, 40 mg/mL and 80 mg/mL, of Pfizer Inc.The Product is indicated for the treatment of Allergic States, Dermatologic Diseases, Endocrine Disorders, Gastrointestinal Diseases, Hematologic Disorders, Neoplastic Diseases, Nervous System, Ophthalmic Diseases, Renal Dise...